mechnikov institute, s.a.
OUR PRODUCTS
Flu-M
Inactivated Split Influenza Vaccine
Upcoming products
Flu-М
Flu-M® [Influenza vaccine split virion, inactivated]
FLU-M® [Influenza Vaccine (Split Virus, Inactivated)] contains 6 antigens (surface and internal) of subtype A (H1N1), subtype A (H3N2) and type B influenza viruses. It is a highly purified trivalent vaccine in phosphate buffered saline.
The main characteristics of the active ingredients of the FLU-M vaccine and the indicator of its quality consist of its ability to develop an efficient immune response against the strains that circulate in the world in the current epidemiological season.

The technological production process guarantees optimal conditions adapted to:

  • Support the components that intervene in the necessary defense to guarantee the effective interaction "antigen-antibody" and preserve the so-called "epitopes that intervene in the defense".
  • Manufacture pharmaceutical products that meet all international requirements.

Hemagglutinin is the main protective antigen which is an integral membrane protein with a tendency to aggregation. The composition of the FLU-M® vaccine includes a stabilizer that prevents hemagglutinin aggregation and the loss of its antigenic properties..

The FLU-M® vaccine is produced using highly purified antigens of low reactogenicity.

Its immunobiological activity properties meet international requirements for influenza vaccines and guarantee the development of immunity against influenza after its application.
Final composition of FLU-M®
Flu-M® [Influenza vaccine split virion, inactivated]
Active ingredients
Auxiliary substances:
INACTIVATED SPLIT INFLUENZA VACCINE
ISIV [INACTIVATED SPLIT INFLUENZA VACCINE]

The INACTIVATED SPLIT INFLUENZA VACCINE brings together 6 antigens (superficial and internal) of the subtype A (H1N1), subtype A (H3N2) and type B influenza virus. It is a highly purified trivalent vaccine in phosphate-buffered saline.

The main characteristics of the active ingredients of the vaccine and the indicator of its quality consist of its ability to develop an efficient immune response against the strains that circulate in the world in the current epidemiological season.
The technological production process guarantees optimal conditions adapted to:

  • Support the components that intervene in the necessary defense to guarantee the effective interaction "antigen-antibody" and preserve the so-called "epitopes that intervene in the defense".
  • Manufacture pharmaceutical products that meet all international requirements.

Hemagglutinin is the main protective antigen which is an integral membrane protein with a tendency to aggregation.

INACTIVATED SPLIT INFLUENZA VACCINE has a relatively low degree of side effects, its immunobiological activity properties meet international requirements for influenza vaccines and ensure the development of immunity against influenza after its application.
Final composition of the VAIF
(Fractionated inactivated influenza vaccine)
Active ingredients
Auxiliary substances:
CoviVac
[CORONAVIRUS VACCINE, INACTIVATED WHOLE VIRION, PURIFIED, CONCENTRATED]
Vaccine for the prevention of the novel coronavirus infection SARS-CoV-2 (COVID-19)
The CoviVac vaccine is a purified, concentrated suspension of the “AYDAR-1” strain of the SARS-CoV-2 coronavirus obtained in a continuous culture of Vero cells, inactivated with beta-propiolactone.

1 Dose of 0.5 mL contains:

Active ingredients:

• Inactivated SARS-CoV-2 coronavirus antigen*: not less than 3 μg.


Excipients:
• Aluminum hydroxide: 0.3-0.5 mg
• Phosphate buffered saline: up to 0.5 mL
(sodium chloride, disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, water for injections).

Does not contain antibiotics or preservatives.
______________________________________________________________________________________________________________________________________
*Obtained by culture medium on the Vero cell line, inactivated with beta-propiolactone.
FLU-М Tetra
[INFLUENZA VACCINE (SPLIT VIRUSES, INACTIVATED)]
FLU-M® Tetra vaccine [Influenza vaccine (split virus, inactivated)] is a tetravalent vaccine produced in multidose and single-dose vial presentations.
QUALITATIVE AND QUANTITATIVE COMPOSITION
FLU-M® Tetra is a mixture of highly purified surface protective antigens and internal influenza virus antigens, equivalent to subtypes A (H1N1, H3N2) and type B (Yamagata and Victoria lineages), in phosphate buffered saline. Influenza viruses are grown in chicken embryos and inactivated with betapropiolactone.

The antigenic composition of the vaccine is modified every year according to the WHO recommendations for the northern and southern hemispheres of the current epidemiological season.

One 0.5 mL dose contains:

Active ingredients:

  • Influenza virus subtype A(H1N1) hemagglutinin – 15 µg HA
  • Influenza virus subtype A(H3N2) hemagglutinin – 15 µg HA
  • Hemagglutinin of influenza type B (Victoria lineage) – 15 µg HA
  • Hemagglutinin of influenza type B (Yamagata lineage) – 15 µg

Excipients:

  • Thiomersal (preservative) – 50 µg (for multi-dose presentations) or without preservative (for single-dose presentations)
  • Triton X-100 (stabilizer) ≤100 µg
  • Phosphate buffered saline up to 0.5 mL (sodium chloride, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, water for injections)